Genetics of individualizing patient care

Critical Care Medicine

Volumn 35, Issue 1, 2007, Pages 287-288

  Pinsky, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; TUMOR NECROSIS FACTOR ALPHA;

DISEASE SEVERITY; EDITORIAL; GENETIC LINKAGE; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT CARE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

CRITICAL CARE; GENETIC PREDISPOSITION TO DISEASE; HOSPITAL MORTALITY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE PLANNING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN C; SEPSIS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33845955757     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000251491.78149.69     Document Type: Editorial

References (12)

1. Angus CD, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1309
2. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
3. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
4. Reinhart K, Waheedullah K: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 2001; 29(Suppl):S121-S125
5. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
6. Westendorp RG, Langermans JA, de Bel CE, et al: Release of tumor necrosis factor: An innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 1995; 171:1057-1060
7. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
8. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94:3195-3199
9. Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91:3574-3581
10. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-a promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
11. Walley KR, Russell JA: Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35:12-17
12. Pinsky MR: Genetic testing: Costs and access to ICU care. Crit Care Med 2003; 31(Suppl):S411-S415